Skip to main content
SpringerLink
Log in

Glucose Intolerance with Atypical Antipsychotics

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Previous studies have suggested that the atypical antipsychotics clozapine and olanzapine may be associated with an increased risk of glucose intolerance and diabetes mellitus. Early studies have also suggested an association between use of conventional antipsychotics and the development of glucose intolerance.

Objective: To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs.

Methods: All reports suggestive of glucose intolerance for clozapine, olanzapine and risperidone were identified in the WHO database for adverse drug reactions. In the analyses of possible risk factors for glucose intolerance all other reports of adverse drug reactions for clozapine, olanzapine and risperidone were used as reference. Using the Bayesian Confidence Propagation Neural Network method, the strengths of the associations over time between glucose intolerance and the use of these drugs were analysed. For comparison, the strengths of the associations between glucose intolerance and the use of the conventional antipsychotics haloperidol and chlorpromazine were also analysed.

Results: Clozapine, olanzapine and risperidone were significantly associated with glucose intolerance. In contrast, chlorpromazine and haloperidol were not associated with glucose intolerance. For clozapine, olanzapine and risperidone grouped together, the following potential risk factors for glucose intolerance were identified: an underlying diabetic condition (odds ratio [OR] 10.22, 95% CI 8.20–12.73), an increase in weight (OR 2.36, 95% CI 1.76–3.17), male gender (OR 1.27, 95% CI 1.11–1.47), and concomitant use of valproic acid (OR 1.97, 95% CI 1.61–2.40), selective serotonin reuptake inhibitors (OR 1.63, 95% CI 1.33–1.99) or buspirone (OR 2.24, 95% CI 1.33–3.77).

Conclusion: Treatment with clozapine, olanzapine or risperidone appears to be associated with an increased risk of glucose intolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II
Fig. 4

Similar content being viewed by others

References

  1. Waddington JL, O’Callaghan E. What makes an antipsychotic agent ‘atypical’? conserving the definition. CNS Drugs 1997; 7: 341–6

    Article  CAS  Google Scholar 

  2. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000; 22(3): 195–214

    Article  PubMed  CAS  Google Scholar 

  3. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108–11

    Article  PubMed  CAS  Google Scholar 

  4. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83

    Article  PubMed  CAS  Google Scholar 

  5. Hägg S, Joelsson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9

    Article  PubMed  Google Scholar 

  6. Melkersson KI, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783–91

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438–43

    Article  PubMed  CAS  Google Scholar 

  8. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865–7

    Article  PubMed  CAS  Google Scholar 

  9. Arnesson GA. Phenothiazine derivates and glucose metabolism. J Neuropsychiat 1964; 5: 181–98

    Google Scholar 

  10. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalised women. Am J Psychiatry 1968; 124: 978–82

    PubMed  CAS  Google Scholar 

  11. Proakis AG, Mennear JH, Miya TS, et al. Phenothiazines-induced hyperglycemia: relation to CNS and adrenal effects. Proc Soc Exp Biol Med 1971; 137: 1385–8

    PubMed  CAS  Google Scholar 

  12. Schwarz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 1968; 125: 253–5

    PubMed  CAS  Google Scholar 

  13. Ward JL. Glucose tolerance in schizophrenia. Orthomol Psychiatry 1972; 44: 137–40

    Google Scholar 

  14. Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 1969; 30: 341–4

    PubMed  CAS  Google Scholar 

  15. McKee HA, D’Arcy PF, Wilson P. Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 1986; 11: 297–9

    PubMed  CAS  Google Scholar 

  16. Brambilla F, Guastalla A, Guerrini A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37: 98–103

    PubMed  CAS  Google Scholar 

  17. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68–73

    Article  PubMed  CAS  Google Scholar 

  18. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463–72

    Article  PubMed  CAS  Google Scholar 

  19. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63

    Article  PubMed  CAS  Google Scholar 

  20. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81

    Article  PubMed  CAS  Google Scholar 

  21. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079–81

    PubMed  CAS  Google Scholar 

  22. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98–101

    Article  PubMed  CAS  Google Scholar 

  23. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2

    PubMed  CAS  Google Scholar 

  24. Brömel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76–80

    Article  PubMed  Google Scholar 

  25. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312–4

    PubMed  CAS  Google Scholar 

  26. Melamed Y, Mazeh D, Elizur A. Risperidone treatment for a patient suffering from schizophrenia and IDDM [letter]. Can J Psychiatry 1998; 43: 956

    PubMed  CAS  Google Scholar 

  27. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315–21

    Article  PubMed  CAS  Google Scholar 

  28. Orre R, Lansner A, Bate A, et al. Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Anal 2000; 34: 473–93

    Article  Google Scholar 

  29. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16: 77–89

    Article  PubMed  CAS  Google Scholar 

  30. Edwards IR, Wiholm B-E, Martinez C. Concepts in risk-benefit assessment. Drug Saf 1996; 15: 1–7

    Article  PubMed  CAS  Google Scholar 

  31. Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001; 16: 63–73

    Article  PubMed  CAS  Google Scholar 

  32. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  33. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51

    Article  PubMed  Google Scholar 

  34. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in diabetes mellitus. J Clin Psychiatry 1995; 56: 128–36

    PubMed  CAS  Google Scholar 

  35. Petty KJ. Hyperglycemia associated with paroxetine [letter]. Ann Intern Med 1996; 125: 782

    PubMed  CAS  Google Scholar 

  36. Erenmemisoglu A, Ozdogan UK, Saraymen R, et al. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hypeglycemic mice. J Pharm Pharmacol 1999; 51: 741–3

    Article  PubMed  CAS  Google Scholar 

  37. Yamada J, Sugimoto Y, Inoue K. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 1999; 382: 211–5

    Article  PubMed  CAS  Google Scholar 

  38. Good MI. Lethal interaction of clozapine and buspirone? Am J Psychiatry 1997; 154: 1472–3

    PubMed  CAS  Google Scholar 

  39. Uvnäs-Moberg K, Ahlenius S, Alster P, et al. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 1996; 63: 269–74

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors have no financial or other conflicts of interest that are directly relevant to the contents of the manuscript.

The authors are indebted to the national centres mentioned in this study, who contributed data. The opinions and conclusions, however, are not necessarily those of the various centres nor of the WHO.

Author information

Authors and Affiliations

  1. Drug Epidemiology Unit, Medical Products Agency, Box 26, Uppsala, S-751 03, Sweden

    Karin Hedenmalm & Örjan Mortimer

  2. Division of Clinical Pharmacology, Norrland University Hospital, Umeå, Sweden

    Staffan Hägg

  3. WHO Uppsala Monitoring Centre, Uppsala, Sweden

    Malin Ståhl

  4. Department of Clinical Pharmacology, St Olav’s University Hospital, Trondheim, Norway

    Olav Spigset

Authors
  1. Karin Hedenmalm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Staffan Hägg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malin Ståhl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Örjan Mortimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olav Spigset
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Hedenmalm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hedenmalm, K., Hägg, S., Ståhl, M. et al. Glucose Intolerance with Atypical Antipsychotics. Drug-Safety 25, 1107–1116 (2002). https://doi.org/10.2165/00002018-200225150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225150-00005

Keywords

Search

Navigation